PMDA drug package insert
エフェクト内服液
PMDA OTC drug · ムサシノ製薬（株） · package insert Apr 29, 2026
Key facts
| Brand names | エフェクト内服液 |
|---|---|
| Companies | 製造販売元／日本医薬品製造（株）,販売会社／ムサシノ製薬（株） |
| Product type | OTC drug |
| OTC risk class | 第２類医薬品 |
| OTC dosage form | 液剤 |
| OTC effect category | ビタミン含有保健薬（ビタミン剤等） |
| Package insert date | Apr 29, 2026 |
| PMDA document key | 530170_J0601004412 |
| PMDA company code | 530170 |
At a glance
- 1–9 Package insert revisions
- None Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: